Trametinib Decreased Intracerebral Hemorrhages and Endothelial-to-Mesenchymal Transition in KRASG12V-Induced Brain Arteriovenous Malformations in Mice.

BACKGROUND

Brain arteriovenous malformations (bAVMs) are a major risk factor for intracerebral hemorrhages in young patients. Recent clinical studies have reported that the majority of human bAVMs harbor somatic KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations. In our previous study, we confirmed the causal role of endothelial KRASG12V mutation in bAVM development in mice through hyperactivation of the MEK/ERK (mitogen-activated protein kinase kinase/extracellular signal-regulated kinase) pathway. However, the treatment efficacy of targeting MEK/ERK signaling in bAVMs, regarding clinical and biological outcomes, remains unclear.

METHODS

In this study, we used the US Food and Drug Administration-approved MEK inhibitor, trametinib, to treat mice with bAVMs induced by brain endothelial cell (EC)-specific KRASG12V overexpression (KRASG12V/bEC mice). We treated KRASG12V/bEC mice with either vehicle or trametinib and evaluated outcomes on mortality and the alteration of bAVMs, and the hemorrhages. We also determined the effect of trametinib on the endothelial-to-mesenchymal transition, which has recently been explored in human bAVMs and implicated in bAVM pathology, in bAVMs of KRASG12V/bEC mice and cultured mouse ECs transfected with KRASG12V (ECG12V).

RESULTS

We observed that trametinib significantly improved survivability, potentially through improved vessel integrity and reduction in the severity of bAVM ruptures. Our longitudinal observation of mice bAVMs using noninvasive magnetic resonance imaging revealed that trametinib decreased the total hemorrhagic volume at 8 weeks of treatment when administered at 1 mg/kg compared with the vehicle group, which was confirmed by histological analyses. In addition, trametinib altered endothelial-to-mesenchymal transition by reducing the expression levels of mesenchymal markers (N-Cad [N-cadherin], Slug, CD44 [cluster of differentiation 44]) and increasing an EC marker (VE-Cad [vascular endothelial cadherin]) in bAVMs of KRASG12V/bEC mice. Trametinib also decreased proliferation (Ki-67) and angiogenic (CD34 and pVEGFR2 [phosphor-vascular endothelial growth factor receptor 2]) markers in KRASG12V/bEC mice's bAVMs. We also confirmed that trametinib normalized the endothelial-to-mesenchymal transition-associated marker expression and functions in ECG12V.

CONCLUSIONS

Our data demonstrate that trametinib improves bAVM pathology by reducing hemorrhagic risk and normalizing endothelial-to-mesenchymal transition. These findings suggest that trametinib is a promising agent to treat patients with bAVM.